psychiatryRounds

Connecting Psychiatry - Expert community for all mental health professionals

Depression and Comorbid Anxiety: An Overview of Pharmacological Options

(PSYCHIATRIC TIMES) - Psychiatric Times - Category 1 CreditTo earn AMA PRA Category 1 Credit(s)™:
Read the article "Depression and Comorbid Anxiety: An Overview of Pharmacological Options" from the June 2009 issue of Psychiatric Times, complete the posttest and the evaluation. (Note: A score of at least 70% must be achieved in order to be awarded credit.)

The posttest will be scored instantly and results will be shown onscreen. Please make a copy of your test results for your continuing education records. After submitting the activity evaluation, you may then print a Statement of Credit for your records.

You must keep your own records of this activity. Copy this information and include it in your continuing education file for reporting purposes.

CME LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME LLC designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME LLC is approved by the California Board of Registered Nursing, Provider No. CEP12748, and designates this educational activity for 1.5 contact hours for nurses.

The American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ toward recertification requirements.

The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Educational Objectives

After reading this article, you will be familiar with:

• Ways to recognize and assess comorbid depression and anxiety
• Pharmacological treatment approaches
• Treatment for comorbidity of depression and specific anxiety disorders

Who will benefit from reading this article?
Psychiatrists, psychologists, primary care physicians, nurse practitioners, and other health care professionals. To determine whether this article meets the continuing education requirements of your specialty, please contact your state licensing and certification boards.

Although depressive and anxiety disorders are classified as distinct groups of illnesses, studies document their frequent co-occurrence and provide evidence of a common biological substrate and a shared vulnerability.1 Comorbid depression and anxiety disorders are most frequently seen in primary care and in the general community, and the prevalence of comorbidity has been estimated to be as high as 10% to 20%.1 The comorbidity of depression and anxiety tends to have an earlier age of onset, increased severity of illness, more functional impairment, and poorer outcome (including greater risk of suicide) than does depression or anxiety alone.2 Research data and clinical experience suggest that depression comorbid with anxiety disorders may show less robust response to both pharmacotherapy and psychosocial interventions and may lead to more residual symptoms and increased vulnerability to relapse.3,4

For full article, please visit:
http://www.psychiatrictimes.com/anxiety/article/10168/1421225

Views: 5

Comment

You need to be a member of psychiatryRounds to add comments!

Join psychiatryRounds


psychiatryRounds Social Media

Sponsors

CMEinfo: Board Reviews in Anesthesia, Cardiology, Internal Medicine, Radiology

© 2019   Created by PsychiatryRounds Team.   Powered by

Badges  |  Report an Issue  |  Terms of Service